Portfolio / Nutrileads

Logo-Argenx.jpg

Argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer.

They are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Argenx is listed on NASDAQ and Euronext Brussels.

Company: argenx

Fund: I

Status: Realized

Team member:

Harrold van Barlingen

19.jpg
 

Technology:

Therapeutics

Icons-Creteria_Medical-technologymedical-devices.png